news aktuell GmbH

R-Biopharm starts commercialization of the fully automated RIDA®UNITY system for real-time PCR in molecular diagnostic laboratories

Share

Darmstadt, July 19, 2022 – As a fully integrated solution, the new and completely automated RIDA®UNITY system combines sample extraction, PCR setup, real-time PCR and result evaluation in a common workflow. The biotechnology company R-Biopharm AG announced today that it has received the CE mark and will begin selling the new, fully automated RIDA®UNITY system for molecular detection of infectious diseases throughout Europe.

"With the RIDA®UNITY system, R-Biopharm is purposefully taking the path from a provider of individual solutions to a system provider in the field of molecular diagnostics," stated Christian Dreher, CEO of R-Biopharm. "We are very happy to make this system solution available to all molecular biology laboratories throughout Europe."

Unique combination of different tools

The RIDA®UNITY system combines the various steps in the analysis of patient samples into an integrated workflow – nucleic acid extraction, PCR setup, subsequent real-time PCR and the evaluation of the results run fully automatically without user intervention. The ready-to-use RIDA®UNITY reagents significantly reduce the preparation times in the laboratory. The RIDA®UNITY Universal Extraction Kit allows the universal extraction of nucleic acids from both gastrointestinal and respiratory patient samples in a common workflow and was specifically developed and optimized by R-Biopharm. Up to six different RIDA®UNITY PCR assays can now be individually combined and processed.

The software especially developed for the RIDA®UNITY system supports the user with its simple and intuitive operation – from loading the required consumables and positioning the PCR reagents on the deck up to evaluating the final results. The RIDA®UNITY system supports molecular diagnostic laboratories with its flexibility in dealing with quickly changing requirements and thus noticeably facilitates everyday work in the laboratory.

"Today we can finally present the result of an incredible effort of diverse teams and many colleagues both from internal as well as external sources," says Dr. Lena Kastl, Vice President Clinical Diagnostics at R-Biopharm. "R-Biopharm's many years of product development and manufacturing expertise and the productive cooperation with various partners made the roll-out of this new molecular diagnostic platform possible. Thanks to its efficient, intuitive and universal application options, RIDA®UNITY will significantly support and improve workflow and capacities in the laboratories in the future.”

The RIDA®UNITY System, the RIDA®UNITY Universal Extraction Kit and the RIDA®UNITY Bacterial Stool Panel are now available for sale throughout Europe. Further assays for gastrointestinal and respiratory pathogens will follow in the coming months.

Contacts

Press contact:
Simone Feiler
Head of Corporate Brand Communication
https://r-biopharm.com
https://r-biopharm.com/contact/
https://r-biopharm.com/news-press/download-gallery/
R-Biopharm AG
An der neuen Bergstraße 17
64297 Darmstadt
Germany
Phone: +49 61 51 - 81 02-538
Email: s.feiler@r-biopharm.de

Images

About news aktuell GmbH

news aktuell GmbH
news aktuell GmbH
Mittelweg 144
20148 Hamburg

+49 (0)40 4113-32589http://www.newsaktuell.de

As wholly owned subsidiary of dpa, news aktuell provides business and organizations with effective access to media and consumers. Via the smart tools ots and zimpel, PR content accesses all media formats, including classical print, high click-rate online portals and social networks. In addition, news aktuell publishes all its customers’ PR content on www.presseportal.de, one of the PR portals with the greatest reach in Germany. By this means, all the relevant multipliers are reached globally, from editors, via digital influencers right up to specialist bloggers and interested consumers. news aktuell has been on the market since 1989. The company, with a staff complement of more than 135, has its headquarters in Hamburg. Other offices are in Berlin, Dusseldorf, Frankfurt und Munich.

Subscribe to releases from news aktuell GmbH

Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from news aktuell GmbH

Grünenthal to license osteoarthritis pain treatment to Shionogi in Japan in deal of up to > $ 500 million4.8.2022 09:00:00 CEST | Press release

Aachen, Germany – 4 August 2022 – Grünenthal and Shionogi announced today that they have entered into a licensing agreement for Grünenthal’s investigational medicine Resiniferatoxin (“RTX”). Shionogi obtained the exclusive rights to commercialise Grünenthal’s asset in Japan for pain associated with osteoarthritis of the knee. RTX is currently in Phase III of clinical development for the treatment of patients with moderate to severe pain associated with knee osteoarthritis. Osteoarthritis, a progressive and often painful joint disease, is an indication with high unmet medical need. If approved, RTX could become a well-tolerated, non-opioid therapy option for patients, providing long-lasting pain relief and functional improvement of the affected knee joints. Under the terms of the agreement, Shionogi will obtain the exclusive commercialisation rights for RTX in Japan for a total consideration of up to $ 525 million plus additional sales based payments. Thereof, Shionogi will pay $ 75 mil

Make some noise for endangered species: Krombacher and Wacken Open Air present the "Growling Creatures" – the first metal band consisting of endangered animals1.8.2022 10:48:17 CEST | Press release

Krombach / Germany, August1st 2022. What do grey seals, cuckoos, and lynx have in common? They are all rare, European native species whose survival is threatened, and they are part of the "Growling Creatures" - the first metal band consisting of endangered animals. Presented by Krombacher and the legendary metal festival Wacken Open Air (W:O:A), this summer the Growling Creatures are drawing attention to their threat and are making some noise for endangered species. "With Krombacher, we have long been committed to domestic and international species protection projects," says Peter Lemm, Head of Communications of the Krombacher brewery. "As a new partner of the Wacken Open Air, it was important for us to create an authentic connection between our sustainable commitment and entertainment with a twinkle in the eye. The Growling Creatures represent exactly this - as musical newcomers of the year, they deliver the best metal sound for the good cause." Animalistic Metal Sound On their mini-E

After cake attack on Mona Lisa: Castello CUBE has to be hidden in a safe in the Swiss Alps!14.7.2022 13:30:00 CEST | Press release

Zug, Switzerland - It is the most expensive cube ever made, funded by the booming cryptocurrency Castello Coin. For now, the world-famous Castello CUBE will no longer be open to the public – to protect it from damage and theft. The Castello CUBE attracted worldwide attention when the golden cube by artist Niclas Castello was shown first in New York's Central Park and at the Venice Biennale this year. The work of art, unique in the world, was made of 24 carats, 999.9 fine gold in the oldest art foundry in Europe and weighs 410 lbs. The material value alone is $11.7 Million US-Dollars. Coin and CUBE each act as a bridge between the classic financial world, the world of traditional forms of investment and traditional art and the new world – the world of cryptocurrencies and the digital age. Initially, the Cube was supposed to be shown in other locations in the US, Europe, Asia and the United Arab Emirates and inspire people worldwide. But security experts advise against it after a risk an

Grünenthal acquires testosterone treatment NebidoTM from Bayer14.7.2022 08:24:23 CEST | Press release

Grünenthal acquires NebidoTM from Bayer AG for up to € 500 million. The product is expected to add about € 100 million to Grünenthal’s EBITDA in 2023. NebidoTM is the gold standard for the treatment ofmale hypogonadism associated with testosterone deficiency. It is available to patients in over 80 markets worldwide. Grünenthal has invested over € 2 billion in successful M&A transactions over the last years, resulting in a significantly strengthened profitability. Aachen, Germany, 14 July 2022 –Grünenthal, a global science-based, privately-owned pharmaceutical company, today announced an agreement with Bayer AG to acquire NebidoTM, the well-known brand for the treatment of male hypogonadism and its associated brands for up to € 500 million. NebidoTM is the only long-acting injectable treatment for testosterone deficiency. The product is approved and successfully commercialized in over 80 countries. Patent protection exists until March 2024 in the EU and until May 2027 in the US. The bra

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom